KMDA

Kamada Issues 2024 CEO Letter to Shareholders

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, KMDA, CMV, Hospital, Division, EMA, CSL Behring, Letter, Physician, Critical care, FDA, Technology transfer, Food, Growth, FEV1, AAT, Immunoglobulin G, Safety, University, European Medicines Agency, Food and Drug Administration, Pan American Health Organization, Patient, Plasma, Research, Partnership, Pharmaceutical industry

The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.

Key Points: 
  • The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.
  • Looking ahead, we expect the momentum from 2023 to extend throughout 2024, with profitability to be further increased as compared to last year.
  • These significant catalysts are propelling our continued annual double-digit profitable growth with substantial upside potential and limited downside risk.
  • On behalf of the entire Kamada team, we look forward to continuing to support patients and clinicians with the important lifesaving products that we develop, manufacture, and commercialize.

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Retrieved on: 
Wednesday, March 6, 2024
KMDA, FDA, Food, Growth, Agency, DSMB, Pharmaceutical industry

“Total revenues for 2023 were $142.5 million, representing record annual revenues and 10% year-over-year growth, and adjusted EBITDA was $24.1 million, up 35% year-over-year.

Key Points: 
  • “Total revenues for 2023 were $142.5 million, representing record annual revenues and 10% year-over-year growth, and adjusted EBITDA was $24.1 million, up 35% year-over-year.
  • Specifically, we are introducing full-year 2024 revenue guidance of $156 million to $160 million and adjusted EBITDA guidance of $27 million to $30 million.
  • Financial Highlights for the Three Months Ended December 31, 2023
    Total revenues were $36.4 million in the fourth quarter of 2023, compared to $45.4 million in the fourth quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.4 million in the fourth quarter of 2023, compared to $7.2 million in the fourth quarter of 2022.

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Retrieved on: 
Wednesday, February 28, 2024
Eastern Time Zone, KMDA, International, Internet, Kamada

Kamada management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13744277.
  • The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1655132&tp_key=6e560eef4a .
  • The call will also be archived for 90 days on the Company’s website at www.kamada.com.

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Retrieved on: 
Wednesday, December 6, 2023
Marketing, KMDA, Partnership, Eastern Time Zone, FDA, International, Hospital, Growth, Internet, Patient, Immunoglobulin G, Pharmaceutical industry

Within the first four years of the eight-year term, which begins in January 2024, Kedrion will purchase minimum quantities of KEDRAB with revenues to Kamada of approximately $180 million.

Key Points: 
  • Within the first four years of the eight-year term, which begins in January 2024, Kedrion will purchase minimum quantities of KEDRAB with revenues to Kamada of approximately $180 million.
  • In addition, the parties will collaborate to expand distribution of Kedrion products by Kamada in Israel.
  • “We are thrilled to secure this strategic agreement with Kedrion as it represents our largest commercial agreement since Kamada's inception,” said Amir London, CEO of Kamada.
  • Kamada expects a substantial increase in sales of the product to Kedrion for full-year 2023.

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Monday, November 13, 2023
Sale, EBITDA, Three Months, Acquisition, Safety, CMV, International, Investment, S&M, SDF, Depreciation, Patient, DSMB, Internet, FDA, G&A, KMDA, Data monitoring committee, Eastern Time Zone, Availability, Innova (video game company), FIMI, Table, R, Growth, Nine Months, Coronavirus Scientific Advisory Board, TASE, Immunoglobulin G, Clothing, Pharmaceutical industry, Fine chemical, Security (finance), Video game, Reinsurance, Kamada

“Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.

Key Points: 
  • “Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.
  • Financial Highlights for the Three Months Ended September 30, 2023
    Total revenues were $37.9 million in the third quarter of 2023, an 18% increase from the $32.2 million recorded in the third quarter of 2022.
  • S&M costs, for the third quarter of 2023 and 2022, included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Retrieved on: 
Wednesday, November 8, 2023
TASE, Eastern Time Zone, International, KMDA, Kamada, Internet

Kamada management will host an investment community conference call on Monday, November 13, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Monday, November 13, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13741701.
  • The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1637192&tp_key=fd85a910fe .
  • The call will also be archived for 90 days on the Company’s website at www.kamada.com.

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Retrieved on: 
Monday, October 16, 2023
Transfer, Kamada, Food, Division, CSL Behring, Research, University of Texas Southwestern Medical Center, Pancreas, Cytomegalovirus, Critical care, Liver, Heart, Holocene, Immunoglobulin G, Safety, University, Transplant, Survival, Tobacco Products Scientific Advisory Committee, FDA, Kidney, Food and Drug Administration, Lung, Availability, KMDA, TASE, Patient, CMV, Pharmaceutical industry

Kamada announced that CYTOGAM manufactured at the Company’s facility in Beit Kama, Israel, is now available for commercial sales in the U.S.

Key Points: 
  • Kamada announced that CYTOGAM manufactured at the Company’s facility in Beit Kama, Israel, is now available for commercial sales in the U.S.
  • This follows the recent FDA approval of the technology transfer process of CYTOGAM from its previous manufacturer, CSL Behring.
  • The availability of Kamada-manufactured CYTOGAM in Canada is expected later this year.
  • The advisory board focuses on Kamada’s newly implemented U.S. clinical program for CYTOGAM including new opportunities and future research and development possibilities.

Kamada Provides Corporate Update on its Israel Operations

Retrieved on: 
Tuesday, October 10, 2023
KMDA, TASE, Fine chemical

Kamada will provide further updates if and when material events so warrant.

Key Points: 
  • Kamada will provide further updates if and when material events so warrant.
  • “We, at Kamada, are profoundly horrified by the devastating terrorist attacks in Israel during recent days.
  • Our deepest condolences, thoughts and prayers are with those impacted by these terrifying events," said Amir London, Kamada’s Chief Executive Officer.
  • While events in Israel are evolving, our global activity and the supply of our products are expected to continue as planned.

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Retrieved on: 
Wednesday, August 30, 2023
Private law, Private, United Kingdom company law, Record, Exchange, KMDA, Doctor of Philosophy, Sale, Regenerative medicine, Private placement, Growth planning, FIMI, Prospectus, Kamada, TASE, Growth, Pursuit, Risk management, Management, Security (finance), MD

Under the terms of the Private Placement, Kamada will be issuing an aggregate of approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the Private Placement).

Key Points: 
  • Under the terms of the Private Placement, Kamada will be issuing an aggregate of approximately 12.6 million ordinary shares to FIMI at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the Private Placement).
  • Upon closing of the Private Placement, expected during the first week of September, FIMI will beneficially own approximately 38% of Kamada’s outstanding ordinary shares and will become a controlling shareholder of the Company, within the meaning of the Israeli Companies Law, 1999 (the "Companies Law").
  • “We are grateful for the support of FIMI and our shareholders in approving the $60 million private placement,” said Amir London, Kamada’s Chief Executive Officer.
  • Any offering of the ordinary shares under the resale registration statement will only be by means of a prospectus.

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Wednesday, August 16, 2023
Loss, International, Table, SDF, Eastern Time Zone, European Medicines Agency, Innova (video game company), G&A, KMDA, Action Replay, EMA, Internet, FIMI, EBITDA, Kamada, Acquisition, Investment, TASE, Immunoglobulin G, Depreciation, Growth, R, Adjustment, FDA, S&M, Second Half, Three Months, FEV1, Fiscal, Video game, Security (finance), Fine chemical, Pharmaceutical industry, Tutoring, Bookkeeping, Cryptocurrency

“Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • Financial Highlights for the Three Months Ended June 30, 2023
    Total revenues were $37.4 million in the second quarter of 2023, a 59% increase from the $23.6 million recorded in the second quarter of 2022.
  • Gross profit and gross margins were $14.4 million and 39%, respectively, in the second quarter of 2023, compared to $7.2 million and 31%, respectively, reported in the second quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the second quarter of 2023, as compared to $1.3 million in the second quarter of 2022.